FIGURE 10.

Prophylactic treatment of 10-wk-old MRL/lpr mice with anti-CD40 Ab inhibits development of proteinuria, salivary gland inflammation, and joint inflammation. MRL/lpr mice were treated beginning at 10 wk of age with twice-weekly doses of PBS or anti-CD40 at 15 or 1.5 mg/kg, once weekly at 15 mg/kg, or daily with prednisolone. (A) A Kaplan–Meier graph of the percentage of mice that are not proteinuric, defined as urine protein ≤300 mg/dl (n = 18 mice per group). *p < 0.05 Mantel–Cox survival analysis. Pathological features were determined and scored as described in Materials and Methods at study terminus (day 63). (B) Glomerular disease and perivascular infiltration scores are graphed. Numbers of mice per group are: PBS (n = 11), prednisolone (n = 12), and anti-CD40 at 15, 5, and 1.5 mg/kg (n = 5, 4, and 11, respectively). (C) Salivary gland inflammation scores are graphed. Numbers for mice per group are the same as above. (D) Joint inflammation is graphed. Numbers of mice per group are PBS (n = 4), prednisolone (n = 12), and anti-CD40 at 15, 5, and 1.5 mg/kg (n = 8, 11, and 5, respectively). *p < 0.05 Kruskal–Wallis test.